All In Biotech

Drug Trial Radar · NCT04344717

Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Dec 20, 2020

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Short bowel syndrome (SBS) is defined as a loss of function of the small intestine resulting in a malabsorptive disorder. In SBS, oral drug absorption may be altered due to extensive intestinal resection. It remains unclear to what extent apixaban exposure is impacted in SBS.Therefore this study tries to investigate the pharmacokinetics (PK) of apixaban in adult patients with SBS requiring long-term parenteral nutrition (PN).

Conditions

  • Short Bowel Syndrome
  • Anticoagulation

Interventions

  • Apixaban single doseDrug

    A single dose of apixaban 2.5 mg and 5 mg (wash out period of at least 7 days) will be administered and PK characteristics will be measured

  • Apixaban steady-stateDrug

    Steady-state apixaban PK characteristics will be measured in patients already treated with apixaban

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in Cmax of apixaban between SBS and patients with a normal gastrointestinal tractTime frame: Through study completion, an average of 1.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Leuven

    Leuven, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.